

Membrane-tethered peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as allosteric biased ligands

Hassan Nassour^{1,†}, Tuan Anh Hoang^{1,†}, Ryan D. Martin², Juliana C. C. Dallagnol^{1,2,4}, Étienne Billard^{1,2}, Myriam Létourneau¹, Ettore Novellino³, Alfonso Carotenuto³, Bruce G. Allen⁴, Jason C. Tanny², Alain Fournier¹, Terence E. Hébert², and David Chatenet^{1*}

¹Institut National de la Recherche Scientifique, Centre Armand-Frappier Santé Biotechnologie, Groupe de Recherche en Ingénierie des Peptides et en Pharmacothérapie (GRIPP), Université du Québec, Ville de Laval, Québec, Canada

²Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada

³Department of Pharmacy, University of Naples "Federico II", Naples, Italy

⁴Department of Medicine, University of Montreal, Montreal Heart Institute.

*Corresponding author: Dr. David Chatenet

E-mail: david.chatenet@iaf.inrs.ca

Running title: hUT-pepducins enables urotensin II receptor activation

Keywords: G protein-coupled receptors, pepducins, lipidated peptides, urotensin II receptor, allosteric modulators, cellular signaling.

Abstract

Over the last decade, the urotensineric system has garnered significant attention as a promising new target for the treatment of various cardiovascular diseases and also cancer. Significant investment toward the development of clinically relevant UT ligands for therapeutic intervention has been made but have met little to no success to date. The UT system, which has yet to be effectively targeted, therefore remains to be therapeutically exploited. The discovery of allosteric sites that allow modulation of receptor activity will increase the searchable chemical space against a disease-relevant target. Pepducins and other lipidated peptides have been used as both mechanistic probes and potential therapeutics. Therefore, pepducins derived from the human urotensin II receptor might represent unique tools to generate signaling bias and study UT signaling networks. Two hUT-derived pepducins, derived from the second and the third intracellular loop of UT, respectively, have been synthesized and pharmacologically characterized. Our results demonstrated that hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 acted as biased ago-allosteric modulators, triggered ERK_{1/2} phosphorylation and to a lesser extent, IP₁ production, stimulated cell proliferation yet were devoid of contractile activity. Interestingly, both hUT-derived pepducins were able to modulate hU_{II}- and URP-mediated contraction albeit to different extents. These new derivatives represent unique tools to reveal the intricacies of hUT signaling and also a novel avenue to design allosteric ligands selectively targeting UT signaling that could prove to be useful for the treatment of hUT-associated diseases.

Introduction

In humans, the urotensineric system, composed of a class 1A G protein-coupled receptor (hUT), and two endogenous peptide ligands, urotensin II (U_{II}; hU_{II} = H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) and urotensin II-related peptide (URP, H-Ala-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH), continues to represent a promising contemporary target for the treatment of several pathologies (1,2). Notably, multiple studies in animal models have suggested that UT antagonists may represent potential therapeutic agents for treating atherosclerosis (3-6), pulmonary arterial

hypertension (7-9), metabolic syndrome (4), and heart failure (10-12). However, in spite of such promise, clinical studies of UT antagonist drug candidates have had limited success due to a lack of efficacy in humans (1,2,13,14). Our current knowledge is therefore insufficient to clearly assess the therapeutic potential of this system and accordingly, a deeper understanding of UT pharmacology is critically needed to accelerate the development of new UT ligands exhibiting efficacy in humans.

While the two endogenous ligands share a common bioactive core, the distinct N-terminal domain of U_{II} isoforms appears to be involved in specific topological changes associated with UT activation (2,15-17). Contingent on their interactions with UT, U_{II} and URP probably induce distinct UT conformational and dynamic changes that lead to divergent signaling profiles with both common and distinct biological activities (2,17-21). Recent years have witnessed the emergence of useful molecules, with probe-dependent actions, that could shed light on the respective roles and importance of U_{II} and URP under normal and pathological conditions (13,17,18,22-27).

Promoting specific GPCR signaling events with biased agonists or allosteric modulators is a potentially innovative way to treat numerous conditions including cardiovascular disease, diabetes as well as neuropsychiatric/neurodegenerative disorders (28). Hence, this notion has been introduced into various drug discovery programs through theoretical predictions based on known signaling components of cells and from studies in knockout animals (reviewed in (29)). However, there are numerous instances where it is still not yet possible to predict what type of signaling bias represents a superior therapeutic approach. In these cases, empirical testing of exemplar molecules in animal models is a way forward. Such tools are currently unavailable in the context of the urotensineric system.

Pepducins are lipidated cell-penetrating peptides composed of a lipid moiety attached to a peptide corresponding to an amino acid segment from one of the cytoplasmic loops of a G protein-coupled receptor (GPCR) of interest (reviewed in (30,31)). Following establishment of an equilibrium between the inner and outer leaflets of the lipid bilayer, pepducins interact with their cognate GPCR leading to stabilization of a restricted subset of its inactive

and active conformational states (32-34). Hence, such compounds can function as allosteric agonists or positive/negative allosteric modulators, making them useful for the study of GPCR signaling, as reported for protease-activated receptors (33,34), chemokine receptors (35,36), and β -adrenergic receptors (37), as well as for the potential treatment of various diseases including inflammatory diseases, cardiovascular pathologies, and cancer (38).

Herein, we describe the design and pharmacological characterization of two pepducins derived from the second (hUT-Pep2) and third ([Trp¹, Leu²]hUT-Pep3) intracellular loops of hUT. Our results demonstrate that both hUT-derived pepducins, while non cytotoxic, trigger ERK_{1/2} phosphorylation and IP₁ accumulation. Using BRET-based biosensors, we observed that UT-Pep3 induced G_q, G_i, β -arrestin 1, β -arrestin 2 activation, and epidermal growth factor receptor (EGFR) transactivation while UT-Pep2 only activated G_i, β -arrestin-2 and EGFR transactivation. Interestingly, while only [Trp¹, Leu²]hUT-Pep3 was able to induce proliferation in HEK 293-hUT cells, both pepducins were able to trigger proliferation of neonatal rat cardiac fibroblasts. Further, while both hUT-derived pepducins are unable to trigger rat aortic ring contraction on their own, they could modulate hUII- and URP-mediated contraction to different extents. These new molecular tools represent unique UT-targeted ligands that can be used to interrogate the involvement of specific pathways in hUT-associated diseases or to develop pharmacological agents with fewer side effects and a unique and more precise action for the treatment of various pathologies.

Results

Design and toxicity testing of hUT-derived pepducins

Pepducins are composed of a synthetic peptide, mimicking an intracellular GPCR loop, to which a hydrophobic moiety, most commonly the fully saturated C₁₆ fatty acid palmitate, is conjugated at their N-terminus (39). Based on a predicted structure for hUT (14,15), pepducins corresponding to the sequence of hUT intracellular loops 2 and 3 (Table 1) were synthesized using solid phase peptide synthesis. hUT-Pep2 is identical to the ICL2

sequence found in hUT. The second pepducin ([Trp¹, Leu²]hUT-Pep3) comprises the hUT ICL3 sequence; however, the first two N-terminal amino acids have been replaced by the corresponding residues from rat UT ICL3 (-Arg-Arg- in hUT and -Trp-Leu- in rUT). This modification was necessary since the pepducin derived from hUT ICL3, comprising at least 7 positively charged residues, was highly cytotoxic, which prevented further use. Nonetheless, as shown in Figure 1A and 1B, hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 (10⁻⁵ M) did not significantly affect HEK 293 cell viability or promote LDH release into culture media, thus demonstrating that both pepducins did not reduce cell viability.

hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 conserve a structure similar to the one adopted within the full-length receptor

Conformational analysis of hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 was performed by solution NMR in DPC micelle suspensions, a solvent system commonly used in NMR and CD studies to mimic the zwitterionic membrane environment (40). hUT-Pep2 gave well-resolved NMR spectra and many NMR parameters indicated a folded structure (Tables S1 and S2). In particular, medium-range Nuclear Overhauser effects (NOEs, Table S2) between H α (i) and HN(i+2) pointed to β -turn structures confirmed by other diagnostic parameters, such as amide temperature coefficients and ³J_{HN-HA} coupling constants. Actually, 135 NOEs (Table S2) were used in structure calculation, which corresponds to 11.2 NOEs per residue, a ratio similar to what is found in structured protein (41). Among those, 22 medium range NOEs in line with folded (β -turn) peptides were observed. Figures of the NOESY spectra of hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 are shown in the supporting information (Figure S1 and S2). Restrained MD calculations provided the well-defined structures shown in Figure 2A. Starting from the N-terminus, two type I β -turns along residues 1-4 and 3-6, and three distorted (type IV) β -turns along residues 4-7, 5-8 and 6-9 can be observed in the simulated structures of hUT-Pep2. Interestingly, the obtained structure can be easily overlapped with the corresponding ICL2 segment of a hUT model recently obtained by us (Figure 2B) (15). hUT-Pep2 therefore preserves the conformational propensities

of the corresponding ICL2 segment embedded in the wild type receptor. Unfortunately, NMR spectra of [Trp¹, Leu²]hUT-Pep3, despite complete assignment of all the proton resonances (Table S3), showed many broad and overlapping signals particularly in the amide proton region that prevented the measure of many NMR parameters (³J_{HN-HA} coupling constants and most of the NOEs), and therefore NMR-based calculation of its 3D structure. However, retrievable NMR parameters from the spectra (a few NOEs, up-field shifts of the H α resonances, and amide temperature coefficients, Tables S3 and S4) suggest a high tendency of [Trp¹, Leu²]hUT-Pep3 to fold into a helix. Using circular dichroism (CD) analyses, we were able to observe that [Trp¹, Leu²]hUT-Pep3, under any condition tested, was able to assume structural motifs (Figure 2C). In 0.1 mg.mL⁻¹ SDS solution (red) it appeared to assume a β -sheet conformation (lower peak at 216 nm), while in TFE solutions it appeared to fold as an α -helix (dark green, TFE 80%, lower peaks at 205 and 216 nm). In 0.5 mg.mL⁻¹ DPC solution, it appeared to assume a less structured α -helix conformation, which correlates with our NMR data, while in water a non-structured shape (random coil) was adopted. Worth noting, a pepducin derived from the ICL3 of PAR1 studied in DPC solutions, also showed a stable helical conformation (42). Together, these results suggest that both pepducins probably adopt conformations closely related to those found within the wild type receptor.

hUT-derived pepducins trigger IP₁ production

To assess hUT-mediated activation of phospholipase C (PLC), the inositol 1,4,5-trisphosphate metabolite inositol monophosphate (IP₁) was quantified. In agreement with previously reported data (43), we observed that hUII peptide induced a time-dependent increase in IP₁ that reached a plateau after 40 min (Figure 3A). Concentration-response curves, constructed after 40 min incubation, revealed that hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 induce IP₁ production in CHO cells stably expressing hUT (Figure 3B) but not CHO mock-transfected cells (data not shown). Compared to hUII, hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 appeared to be less potent (pEC₅₀ < 6) at promoting IP₁ production (Figure 3B), acting as very weak allosteric agonist.

hUT-derived pepducins trigger ERK_{1/2} phosphorylation through different mechanisms

Kinetic measures, using the CHO-hUT cell line (17), revealed that both hUT-derived pepducins induced ERK_{1/2} phosphorylation. Used at 10⁻⁶ M, hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 exerted their maximal effect at 5 min, similar to hUII (Figure 3C). While a second peak was noticeable for UT-Pep3 at 60 min, a similar pattern was not observed for hUT-Pep2, suggesting a potential signaling bias (Figure 3C). We next generated concentration-response curves for each pepducin and hUII (Figure 3D). Compared to hUII, hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 were both less potent (pEC₅₀ = 7.26 \pm 0.14 and 6.70 \pm 0.06, respectively) and less efficacious (E_{max} = 34 \pm 2% and 56 \pm 2%, respectively) at triggering ERK_{1/2} phosphorylation (Figure 3D), behaving as weak partial allosteric agonists.

As shown in Figure 4A, in the absence of the receptor, neither hUII nor hUT-derived pepducins were able to trigger ERK_{1/2} phosphorylation, therefore demonstrating their specificity for hUT. Following pre-treatment of CHO-hUT cells with PTX (a G_{i/o} protein inhibitor), U73122 (a broad range PLC inhibitor), or AG1478 (a specific EGFR inhibitor), ERK_{1/2} phosphorylation was evaluated at 5 min as described above. While PTX and U73122 completely prevented [Trp¹, Leu²]hUT-Pep3-mediated ERK_{1/2} phosphorylation, hUT-Pep2 action was only partially affected by the PLC inhibitor, further supporting distinct mechanisms of action (Figure 4B and 4C). Inhibition of EGFR transactivation with AG1478 significantly reduced the ability of both hUT-derived pepducins to trigger ERK_{1/2} phosphorylation (Figure 4D).

Consistent with our previous results, kinetic experiments, performed this time using a BRET-based biosensor and HEK 293 cells stably expressing hUT, once again revealed biphasic ERK_{1/2} activation following hUII treatment with a maximum activation after 5 min (Figure 5A). hUT-Pep2 (10⁻⁵ M) also reached its maximal effect after 5 min while [Trp¹, Leu²]hUT-Pep3 needed 10 min to reach an efficacy quite similar to what was observed with hUII (10⁻⁷ M). Both hUT-derived pepducins appeared to return to basal levels of ERK_{1/2} activation but with different kinetics: hUT-Pep2 reaching basal levels after 10 min while [Trp¹, Leu²]hUT-Pep3 was still decreasing after 20 min

(around 50%) (Figure 5B and 5C). Pre-treatment with YM254890, a selective inhibitor of G_q signaling, almost completely abolished the ability of hUII to increase $ERK_{1/2}$ phosphorylation while having a modest, but significant, inhibitory effect on the actions of hUT-Pep2 (at 5 min, $*P < 0.05$) and [Trp¹, Leu²]hUT-Pep3 (at 5 and 10 min, $*P < 0.05$) (Figure 5A-C). Interestingly, while hUT-Pep2-mediated $ERK_{1/2}$ phosphorylation returned to basal levels after 10 min, we observed that in the presence of YM254890, a second peak is clearly detectable at 20 min (Figure 5B). Similarly, while a small but significant reduction of $ERK_{1/2}$ phosphorylation is observed with [Trp¹, Leu²]hUT-Pep3 in the presence of YM254890, this activation is maintained and did not decrease over the studied period of time (Figure 5C). Finally, and similar to what was observed in CHO-hUT cells using western blotting, hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 triggered $ERK_{1/2}$ phosphorylation with a lower potency and efficacy than hUII (Figure 6A). Together, these results support a different mode of action related to the regulation of $ERK_{1/2}$ activity by hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3.

Signaling signatures of hUT-derived pepducins

We next investigated the propensity of each pepducin to induce G_q , G_{12} , G_i activation or promote conformational changes at β -arrestin 1 and β -arrestin 2 using BRET-based biosensors. As depicted in Figure 6B-D and Table 2, hUT-derived pepducins can promote activation of G_q , albeit with low efficacy, and G_i but were almost completely unable to activate G_{12} . Notably, on one hand, [Trp¹, Leu²]hUT-Pep3 stimulated G_q activation with a similar potency ($pEC_{50} = 8.34 \pm 0.33$) but a lower efficacy ($E_{max} = 29 \pm 4\%$, $***P < 0.001$) than hUII ($pEC_{50} = 8.19 \pm 0.12$; $E_{max} = 109 \pm 5\%$) acting as a partial allosteric agonist of this pathway (Figure 6B; Table 2). On the other hand, hUT-Pep2 behaved as a weak partial allosteric agonist ($pEC_{50} = 7.31 \pm 0.55$) of this pathway reaching approximately 9% of the hUII maximum response (Figure 6B; Table 2). Interestingly, in contrast to hUII, both hUT-derived pepducins acted as full agonists for the activation of G_i (Figure 6D; Table 2).

We next evaluated the propensity of hUT-derived pepducins to trigger conformational changes in β -arrestin 1 and 2. For β -arrestin 1, [Trp¹, Leu²]hUT-Pep3, which is almost equipotent

($pEC_{50} = 8.08 \pm 0.27$; $**P < 0.01$) compared to hUII ($pEC_{50} = 8.66 \pm 0.13$) but only reached around 18% of its maximum response (Figure 6E; Table 2), acting as a weak partial allosteric agonist for this signaling pathway while hUT-Pep2 appears inactive. For β -arrestin 2, [Trp¹, Leu²]hUT-Pep3, once again acted as a weak partial allosteric agonist, triggering activation of this pathway with low potency ($pEC_{50} = 7.74 \pm 0.32$; $***P < 0.001$) and efficacy ($E_{max} = 19 \pm 3$; $***P < 0.001$) compared to hUII ($pEC_{50} = 9.33 \pm 0.14$; $E_{max} = 100 \pm 3\%$) (Figure 6F; Table 2). hUT-Pep2 behaved as a very weak partial allosteric agonist reaching, at 10^{-6} M, around 15% of the maximal response evoked by hUII or URP. Together, these results demonstrate that both pepducins can trigger hUT activation albeit to different extents.

hUT-derived pepducins promote EGFR transactivation through G_q activation

We next investigated whether UT stimulation by hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 could mediate EGFR transactivation. Untransfected cells and cells stably expressing wild type hUT were transfected with EGFR-GFP and stimulated with either hUII, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 (10^{-6} M). In the absence of stimulation, EGFR had a uniform membrane distribution in HEK 293 cells stably transfected or not with hUT (Figure 7A and 7B). In contrast, treatment with hUII resulted in EGFR internalization as characterized by a marked redistribution into cellular aggregates compared to untreated HEK 293 cells (Figure 7B and 7E). Treatment with hUT-derived pepducins in HEK 293-hUT cells resulted in significant internalization of EGFR-GFP as demonstrated by the punctate distribution of fluorescence (Figure 7H and 7K), which appeared stronger upon [Trp¹, Leu²]hUT-Pep3 stimulation. Finally, we observed that pre-treatment of the cells with the specific G_q inhibitor YM254890 almost completely abolished hUII- as well as UT-derived pepducin-associated EGFR transactivation (Figure 7F, 7I, and 7L). No effects of any of the ligands were seen in mock-transfected cells (Figure 7D, 7G, and 7J). Together, these results revealed that both pepducins can promote EGFR transactivation, albeit to different extents, and that this activation is abrogated following G_q inhibition.

hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 can induce rat neonatal fibroblast proliferation

Several studies have demonstrated the mitogenic properties of UII, URP and related analogs in various cultured cells (1), including rat fibroblasts (44,45), and astrocytes (20), as well as HEK 293-hUT cells (43). In the present study, using HEK 293-hUT cells and two different methods, *i.e.* MTT assays and flow cytometry, we observed that hUII and [Trp¹, Leu²]hUT-Pep3 but not hUT-Pep2 were able to induce HEK 293-hUT cell proliferation (Figure 8A and 8C). Again, in the absence of the receptor, the above described effect was completely abrogated (Figure 8B). Interestingly, using high content imaging, we observed that both hUT-derived pepducins produced a proliferative action in rat neonatal fibroblasts similar to what was observed with hUII (Figure 8D). These observations showed that hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 can act as allosteric agonists promoting cell proliferation and that this action is cell-context dependent, at least for hUT-Pep2.

hUT-derived pepducins can block hUII- and URP-mediated contraction

Since its discovery, UII and its paralog peptide URP have been considered potent vasoconstrictors (1). As shown in Figure 9A, none of the hUT-derived pepducins were able to stimulate contraction reaching only between 5 to 15% of the force induced by hUII or URP in rat aortic ring preparations (Table 3). Used as potential allosteric modulators, hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 suppressed, albeit to different extents, the maximum contractile response to hUII and URP (Figure 9B and 9C; Table 4). For instance, pre-treatment with [Trp¹, Leu²]hUT-Pep3 at 10⁻⁶ M, produced significant suppression of the maximum contractile response to hUII ($E_{\max} = 35 \pm 6\%$; *** $P < 0.001$) and URP ($E_{\max} = 16 \pm 2\%$; *** $P < 0.001$) (Table 3). Similarly, hUT-Pep2 at the same concentration, promoted a significant but small reduction of the maximum contractile response to hUII ($E_{\max} = 86 \pm 3\%$; * $P < 0.05$) and URP ($E_{\max} = 76 \pm 8\%$; ** $P < 0.01$). Interestingly, hUT-Pep2 induced a significant rightward shift in the concentration-response curve of hUII but not URP, therefore suggesting a probe-dependent action. These data demonstrate that hUT-Pep2 but most

importantly [Trp¹, Leu²]hUT-Pep3 can negatively modulate hUII- and URP-mediated contraction.

Discussion

By selectively engaging only a subset of potential intracellular partners, allosteric agonists or biased ligands may offer an unparalleled means to understand and control GPCR-mediated signaling (46). Over the years, the pepducin concept has yielded numerous allosteric agonists and antagonists for several GPCRs, some of them reaching clinical trials (47-49). By stabilizing or disrupting molecular interactions that change the energy landscape of a GPCR, pepducins have the potential to affect the conformational ensemble in ways that affect signaling (50). In the present study, we tested the ability of pepducins, derived from the sequence of intracellular loops 2 and 3 of hUT, to act as functionally-selective modulators. Using various BRET-based biosensors, we demonstrated that hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 showed a clear bias toward the activation of G_i, compared to G_q or G₁₂ activation as well as β -arrestin conformational changes. Most notably, these lipidated peptides, which assumed a 3-dimensional structure similar to those adopted in the full-length receptor and did not show any cytotoxic effects, were both able to act as allosteric biased agonists by promoting hUT-related signaling. Compared to hUII, hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 were able to stimulate, albeit with lower potency and efficacy, ERK_{1/2} phosphorylation through different mechanisms. hUT-Pep2-induced ERK_{1/2} phosphorylation was partially reduced following treatment of the cells with inhibitors of PLC, G_q and EGFR, but unaffected by PTX treatment while the actions of hUII were substantially reduced, or even suppressed, under similar conditions. Therefore, G_i activation does not appear to mediate the effects of hUT-Pep2 on ERK_{1/2} phosphorylation, which likely instead involves G_q, β -arrestin2 as well as EGFR transactivation. Conversely, the drastic reduction in [Trp¹, Leu²]hUT-Pep3-induced ERK_{1/2} phosphorylation following inhibition of G_i or PLC suggested, at first, a possible involvement of G_i and G_q in ERK_{1/2} phosphorylation associated with hUT activation by [Trp¹, Leu²]hUT-Pep3. However, G_i inhibition resulted in only a small, but significant, reduction in the early phase of ERK_{1/2} phosphorylation with a late phase that was both

enhanced and sustained (**Figure 5C**). As previously reported, inhibition of phospholipase C by U73122 can also block receptor-mediated activation of G_i proteins (51,52). GPCRs are known to activate PLC, either *via* GTP-liganded α subunits of the G_q class of G proteins or by $G\beta\gamma$ dimers liberated from G_i proteins (53). Thus, the complete inhibition of $[Trp^1, Leu^2]hUT-Pep3$ -mediated $ERK_{1/2}$ phosphorylation by either PTX or U73122 suggests a direct connection between the two that might involve $G\beta\gamma$ subunits of G_i . In support of this hypothesis, it was demonstrated that dually coupled GPCRs require cooperation of G_i - and G_q -mediated pathways for efficient stimulation of the $ERK_{1/2}$ cascade (54). Several studies have suggested that EGFR transactivation plays a critical role in the hypertrophic response evoked by UT in rat cardiomyocytes (55). Interestingly, such activation was prevented by knockdown of β -arrestins (55). However, as demonstrated, the absence of G protein activation prevents β -arrestin signaling (56). To dissect the mechanism of hUII, hUT-Pep2, and $[Trp^1, Leu^2]hUT-Pep3$ -induced EGFR translocation, we transfected HEK 293-hUT cells with GFP-EGFR and monitored internalization by confocal microscopy. When stimulated with hUII or a hUT-derived pepducins, GFP-EGFR was redistributed from the plasma membrane into endocytic vesicles. Pre-treatment with YM254890 significantly, if not completely, blocked hUII-, hUT-Pep2- and $[Trp^1, Leu^2]hUT-Pep3$ -induced EGFR internalization, indicating a requirement for G_q in their respective responses. Based on previous publications (55), it seems that, at least for hUII, EGFR internalization requires both G_q and β -arrestins.

Following characterization of their signaling signatures in HEK 293-hUT cells, we next investigated the propensity of hUII-, hUT-Pep2 and $[Trp^1, Leu^2]hUT-Pep3$ to promote cell proliferation in heterologous and native cell lines and trigger/block aortic ring contraction. As previously reported, downstream signaling linked to the mitogenic HEK 293-hUT responses obtained following UII treatment involved $ERK_{1/2}$ activation and the RhoA/Rho kinase pathway (43). In the present work, we noted that hUII and $[Trp^1, Leu^2]hUT-Pep3$, but not hUT-Pep2, were able to trigger HEK 293-hUT cell proliferation. Since both hUT-derived pepducins were unable to trigger G_{12} activation, differences in the capacity of hUT-Pep2

and $[Trp^1, Leu^2]hUT-Pep3$ to exert mitogenic actions could arise, at least in part, from their significantly different efficacy to stimulate $ERK_{1/2}$ phosphorylation, with $[Trp^1, Leu^2]hUT-Pep3$ acting as a weak full agonist while hUT-Pep2 behaved as a partial agonist (**Figure 6A**). As previously demonstrated, hUII can induce development of cardiac remodeling by promoting fibroblast mitogenesis (44). Interestingly, and similar to what was observed with hUII, both hUT-derived pepducins promoted proliferation of rat neonatal cardiac fibroblasts. Such differences in the mitogenic action of hUT-derived pepducins on HEK 293-hUT cells and cardiac fibroblasts might be inferred from their different cellular contexts, or differences between receptor isoforms. Indeed, it is now widely accepted that GPCRs can adopt multiple conformations upon ligand binding and that structurally distinct ligands can stabilize functionally distinct conformations (57). However, parameters that influence the mechanisms and the timescales by which ligands induce/stabilize specific conformations will most likely differ depending on cellular context because of disparities in associated signaling proteins and the composition of the lipid bilayer (58,59). Also, despite a similar tissue distribution, structural differences between rat and human UT isoforms (only 75% sequence similarity while rat and mouse UT share more than 95% homology) as well as distinct patterns of putative phosphorylation and palmitoylation sites probably lead to differences in signaling, internalization and desensitization patterns (2). Such differences could therefore also explain the distinct biological activities observed with hUT-Pep2 in HEK 293-hUT cells and rat neonatal fibroblasts. Finally, both endogenous ligands of the urotensinergic system are known as potent vasoconstrictors (1). In the present study, neither UT-derived pepducin exhibited significant contractile action in rat aortic ring preparations. Since aortic ring contraction is in part mediated by intracellular calcium mobilization following activation of G_q (22,23,43) and by the stimulation of the small GTPase RhoA following G_{12} activation (60), the weak contractile potency of hUT-Pep2 and $[Trp^1, Leu^2]hUT-Pep3$ could be explained by their inability to trigger sustained G_{12} and/or G_q activation. This is perhaps not surprising as receptor expression is low. We therefore hypothesized that these pepducins, which mostly act as weak agonists

in overexpressing cells, could behave as modulators of hUII and URP in an endogenous context. We therefore tested whether agonist-stimulated aortic ring contraction was inhibited by either hUT-Pep2 and/or [Trp¹, Leu²]hUT-Pep3. Interestingly, both pepducins were able to reduce hUII- and URP-mediated contraction albeit to different extents. Their mechanisms of action will need further study. However, and as proposed for other reported pepducins, pepducins acting as negative modulators, could 1) compete with their homologous peptide segments, buffering/hindering the interaction of signaling partners and/or components of signaling cascade or 2) interact with complementary regions of the peptide segment, *i.e.* intracellular loops or transmembrane domains, therefore destabilizing (antagonism) receptor conformations and dynamics ultimately modulating associated signaling (33).

Conclusions

Taken together, our results demonstrate that hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3, derived from the intracellular loops 2 and 3, respectively, of hUT can act as biased allosteric agonists/antagonists, engaging/preventing different signaling pathways following UT activation. Given that pepducins are believed to act intracellularly by binding directly to targeted GPCRs on the inner face of the membrane (50,61), it is not surprising to observe that different subsets of downstream effectors than those promoted by the binding of hUII are engaged. Interestingly, while hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 can trigger cell proliferation, this effect appears to be dependent on cellular context. The precise mechanisms of action by which hUT-derived pepducins can promote G_q/G_i activation, EGFR transactivation and fibroblast proliferation are still unknown and will need further investigation. These new molecular tools could represent innovative UT-targeted modulators with unique pharmacological profiles.

Experimental procedures

Cell lines and reagents

HEK 293 cells were purchased from ATCC while the stably transfected HEK 293-hUT cell line was generated in our laboratory (23). Cell culture

reagents were obtained from Invitrogen while antibodies used to evaluate ERK_{1/2} phosphorylation, *i.e.* a rabbit polyclonal antibody against phospho-p44/42 MAPK and an anti-total MAP kinase antibody, were purchased from Cell Signaling Technology. α -Actin antibody was obtained from Abcam (Cambridge, UK). The IP-One ELISA assay kit from CisBio Bioassays. The fluorenylmethyloxycarbamate- (Fmoc-) protected amino-acids, Rink amide AM resin (with Nle), N,N'-diisopropylcarbodiimide (DIC) and ethyl cyanohydroxyiminoacetate (Oxyma) were purchased from Chem-Impex (Wood Dale, IL, USA). Trifluoroacetic acid (TFA), methanol (MeOH), acetonitrile (ACN), diethyl ether, N,N-dimethylformamide (DMF), piperidine, dichloromethane (DCM), and cell mask were obtained from Fisher Scientific (Nepean, ON, Canada). YM254890 was purchased from Cedarlane (Burlington, ON, Canada). All other chemicals, including 99.9% ²H₂O, were from Sigma-Aldrich (Mississauga, ON, Canada). 98% DPC-d₃₈ was obtained from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA), and [(2,2,3,3-tetradeuterio-3-(trimethylsilyl)propionic acid (TSP) from MSD Isotopes (Montreal, QC, Canada).

Synthesis of hUT-derived pepducins

hUT-derived pepducins were synthesized manually using a standard solid phase peptide synthesis approach with Fmoc chemistry. Coupling efficiency was monitored with the qualitative ninhydrin test and a 3-equivalent excess of the protected amino acids, based on the original substitution of the resin (0.50 mmol.g⁻¹), was used in most cases. Coupling of protected amino acids were mediated by DIC (1.5 eq) and Oxyma (1.5 eq) in DCM for 1 h. Fmoc removal was achieved with 20% piperidine in DMF for 20 min. All peptides were cleaved from the resin support with simultaneous side chain deprotection by treatment with TFA containing 1,2-ethanedithiol (2.5%), water (2.5%) and triisopropylsilane (1%) for 1.5 h at room temperature. The diethyl ether-precipitated crude peptides were solubilized in 70% acetic acid (1 mg/mL) and lyophilized prior to purification. Each crude peptide was purified using a preparative reversed-phase HPLC (RP-HPLC) protocol using a linear gradient from eluent A to B with 1% B per 2

min increments (Eluent A = H₂O, 0.1% TFA, Eluent B = 80% CH₃CN/20% H₂O, 0.1% TFA). Homogeneity of purified fractions was assessed by RP-HPLC (eluent system: A = H₂O (0.1% TFA) and B = 100% CH₃CN with a gradient slope of 1% B/min, at flow rate of 1 mL/min on a Vydac C₁₈ column) and MALDI-TOF mass spectrometry in linear mode using α -cyanohydroxycinnamic acid as matrix. Fractions presenting both the correct mass, as evaluated by MALDI-TOF mass spectrometry, and a purity higher than 98%, as confirmed by analytical RP-HPLC, were pooled, lyophilized and stored as a powder until use (**Table 1**). The synthesis of human urotensin II (hUII) was carried out as reported earlier (17,18)

Nuclear magnetic resonance

Samples for NMR spectroscopy were prepared by dissolving the appropriate amount of peptide in 0.54 mL of ¹H₂O (pH 5.5), 0.06 mL of ²H₂O to obtain a final DPC-d₃₈ concentration of 2 mM and 200 mM. NMR spectra were recorded on a Varian INOVA 700 MHz spectrometer equipped with a z-gradient 5 mm triple-resonance probe head. All spectra were recorded at a temperature of 25°C and were calibrated relative to TSP (0.00 ppm) as internal standard. One-dimensional (1D) NMR spectra were recorded in the Fourier mode with quadrature detection. The water signal was suppressed by gradient echo (62). Two dimensional (2D) DQF-COSY (63,64), TOCSY (65), and NOESY (66) spectra were recorded in the phase-sensitive mode as described (67). Data block sizes were 2048 addresses in t₂ and 512 equidistant t₁ values. Before Fourier transformation, the time domain data matrices were multiplied by shifted sin² functions in both dimensions. A mixing time of 70 ms was used for the TOCSY experiments. NOESY experiments were run with mixing time of 100 ms. The qualitative and quantitative analyses of DQF-COSY, TOCSY, and NOESY spectra, were obtained using the interactive program package XEASY (68). Complete ¹H NMR chemical shift assignments were effectively achieved for hUT-Pep2 and [Trp¹, Leu²]hUT-Pep3 according to the Wüthrich procedure (69) *via* the usual systematic application of DQF-COSY, TOCSY, and NOESY experiments with the support of the XEASY software package (Supporting Information, **Tables S1 and S3**). ³J_{αN} coupling constants were measured

by 1D proton and DQF-COSY spectra. Temperature coefficients of the amide proton chemical shifts were calculated from 1D ¹H NMR and 2D TOCSY experiments performed at different temperatures in the range 25–40°C by means of linear regression. Observed NOEs are reported in **Tables S2 and S4** (Supporting Information).

Structure Determination

The NOE-based distance restraints were obtained from NOESY spectrum of hUT-Pep2 collected with a 100 ms mixing time. The NOE cross peaks were integrated with the XEASY program and were converted into upper distance bounds using the CALIBA program incorporated into the DYANA program package (Table S2) (70). An error-tolerant target function (tf-type=3) was used to account for the peptide intrinsic flexibility. From the produced 100 conformations, 10 structures were chosen, whose interproton distances best fitted NOE derived distances, and then refined through successive steps of restrained and unrestrained energy minimization using the Discover algorithm (Accelrys, San Diego, CA) and the consistent valence force field (CVFF) (71). Molecular graphics images were produced using the UCSF Chimera package (72).

Circular dichroism

Circular dichroism (CD) analyses were performed in a JASCO J-815 (JAPAN Spectroscopy & Chromatography Technology) spectropolarimeter coupled to a temperature controller Peltier. Samples were dissolved at 0.2 mg.mL⁻¹ in either water, 0.5 mg.mL⁻¹ DPC (dodecylphosphocholine), 0.1 mg.mL⁻¹ SDS (sodium dodecyl sulfate) or TFE (2,2,2-trifluoroethanol) aqueous solutions at concentrations of 20%, 50% and 80%. The CD spectra were recorded in the measured range of 200–250 nm using a scan speed of 50 nm.min⁻¹, and the baseline was corrected by subtraction of the solvent spectrum. The temperature was set to 20°C.

Cell culture

HEK 293 cells stably transfected with the human urotensin II receptor isoform (HEK 293-hUT) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% of heat-

inactivated foetal bovine serum (FBS), 100 units/mL of penicillin, 100 µg/mL of streptomycin and 2 mM of L-glutamine. Cells were maintained as a monolayer at 37°C in a humidified atmosphere of 5% CO₂ and 95% air and passaged by trypsinization once cells reached 70-80% confluence.

Cell viability

HEK 293 cells were seeded at a density of 2×10^4 cells/well in 96 well-plates and cultured at 37°C for 24 h. Cells were then incubated in serum free media with hUT-derived pepducins at a concentration of 10^{-5} M. Viability was assessed with a MTS kit (CellTiter 96® AQueous, Promega, Madison, WI, USA) and a microplate reader (MTX^{TC} Revelation, Dynex Tech., VA, USA) in order to determine the optical density related to the conversion of MTS into purple-colored water-soluble formazan. Positive control (cells treated with 10% DMSO) and negative control (non-treated cells) were included in each experiment. Results were expressed as the percentage of control (non-treated cells). The presence of lactate dehydrogenase (LDH), released in the culture medium from dead cells, was also determined using a commercial LDH kit (BioVision, Milpitas, CA, USA). Positive control (cells treated with lysis buffer) and negative control (non-treated cells) were included in each experiment. Results were expressed as the percentage of the maximum LDH release following cell lysis.

Western blotting

CHO cells stably expressing hUT (CHO-hUT; gift from Drs H. Vaudry et C. Dubessy, University of Rouen, France) were grown in 12-well plates to 70-80% confluence and starved for 6 h in a serum-free medium. For kinetic experiments, cells were incubated for different time periods (0, 5, 10, 15, 20, 40, 60, and 90 min) with a fixed concentration of hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 (10^{-6} M), hUII (10^{-7} M), or PBS alone (basal control condition). To establish concentration-response curves, cells, seeded as previously described, were stimulated for 5 min with various concentrations of hUII or hUT-derived pepducins (10^{-14} - 10^{-5} M). When applicable, CHO-hUT cells were incubated with either pertussis toxin (PTX, 200 ng/mL) for 24 h, a specific EGFR inhibitor (AG1478; 5 µM) for 30

min or a PLCβ inhibitor (U73122; 1 µM) for 60 min prior their stimulation with hUII (10^{-7} M) or hUT-derived pepducins (10^{-6} M). Similar kinetic experiments were also performed in HEK 293-hUT cells in the presence or absence of a specific G_q inhibitor. Briefly, HEK 293-hUT cells, grown in 12-well plates to 70-80% confluence, were starved for 6 h in a serum-free medium. Cells were treated with YM254890 (100 nM) for 2 min and then incubated for different time periods (0, 5, 10, 15, and 20 min) with a fixed concentration of hUII, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 (10^{-5} M). Cells were then rinsed twice with ice-cold PBS and homogenized in 0.5 mL of lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na₃VO₄, 1 µg/mL leupeptin, 1 mM PMSF, 1 mM DTT) at 4°C. Insoluble material was removed by centrifugation at 12,000 rpm for 30 min. The extract was treated with Laemmli sample buffer and heated for 5 min at 95°C. Aliquots were assayed for protein concentration (BioRad) and an equal amount of total protein was subjected to 12% SDS-PAGE, followed by transfer to a nitrocellulose membrane. The membrane was blocked and then probed with primary antibody (phospho-p44/42 MAPK) at the optimal dilution (1/2000) with gentle agitation overnight at 4°C. After washing with TTBS, membranes were then incubated with secondary antibody, conjugated with horseradish peroxidase (anti-rabbit HRP) diluted in TBST containing 5% skim milk (w/v) for 1 h at room temperature. Immunoreactive species were visualized by enhanced chemiluminescence using X-ray film and Thermo Scientific™ SuperSignal™ chemiluminescent substrates according to the manufacturer's instructions. Films were digitized and the intensity of the immunoreactive bands determined using Quantity One software from BioRad. To confirm equal protein loading in individual lanes, the membrane was stripped and reprobed with antibody against total ERK_{1/2} (diluted 1:5000).

Bioluminescence resonance energy transfer experiments

HEK 293-hUT cells were grown in DMEM culture media supplemented with 10% foetal bovine serum, HEPES, sodium pyruvate and G418 (200 µg/mL). Passages were performed when cells reached 80%

of confluency. Cells were initially plated in 96-well plates at a density of 10,000 cells/well. The following day, the medium is replaced with DMEM culture media supplemented with 2.5% foetal bovine serum (FBS), and 12 h later, cells were transiently transfected with 25 ng/well of a Gq-polycistronic, 25 ng/well of a G₁₂-polycistronic BRET sensor, 2.5 ng β -arrestin 1-polycistronic BRET sensor, or 2.5 ng β -arrestin 2-polycistronic BRET sensor using Lipofectamine[®]2000 at a ratio of 3 to 1 (Lipofectamine/plasmid DNA) in serum-free Opti-MEM (73,74). Sixteen hours post-transfection, medium was replaced with DMEM supplemented with 5% FBS, HEPES, sodium pyruvate and G418 (200 μ g/mL) and cell growth was resumed for another 16 h. Culture medium was changed with fresh medium DMEM/5% FBS (without antibiotics) 5 h later after transfection. Cells were washed with 120 μ L PBS solution supplemented with 0.1% of glucose, and then incubated with 80 μ L of this solution for 2 h. Then, to evaluate G_q and G₁₂ activation, 10 μ L of a 1/20 dilution (diluted before use) of coelenterazine 400A (stock at 1 mM in ethanol) in Kreb's buffer and 10 μ L of the 10x appropriate concentration of peptide were added, and the luminescence was evaluated with an Infinite[®] M1000 PRO. For β -arrestin 1 and 2 pathways, UII, URP, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 at various concentrations was first incubated for 15 min at RT prior adding coelenterazine (10 μ L of a 1/20 dilution). Readings were performed after 5min using an Infinite[®] M1000 PRO. Filters were set at 410 nm and 515 nm for detecting the *Renilla* luciferase II (RlucII, donor) and green fluorescent protein 10 (GFP10, acceptor) light emission, respectively. BRET ratio was determined by calculating the ratio of the light emitted by GFP10 over the light emitted by the RlucII. BRET signals were normalized to that of hUII (10⁻⁶ M).

IP₁ assay

This assay, performed with the IP-One terbium immunoassay kits from Cisbio, was used according to the manufacturer recommendation and as previously described (43). Briefly, CHO-hUT cells were grown in 10-cm dishes for 24 h. The cells were then starved without serum. The next day, cells were washed once with PBS and collected in PBS containing 20 mM EDTA. For the assay,

80,000 cells per well (96-well plate) were used. Cells were treated for various time (10, 20, 40, and 60 min) at 37°C with hUII or treated with increasing concentrations of hUII, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 for 40 min at 37°C. IP₁-d₂ and anti-IP₁-cryptate were added for an additional 2 h at room temperature. Plates were read on a Flexstation 3 microplate reader.

EGFR transactivation

HEK 293 and HEK 293-hUT cells, transiently transfected with cDNA encoding fluorescently labeled EGFR (EGFR-GFP) (2 μ g), were plated onto 35-mm glass-bottomed culture dishes (MatTek Corp, Ashland, MA). Following stimulation, cells were washed once with PBS and fixed in 4% paraformaldehyde for 15 min. To study the involvement of G_q in EGFR internalization, cells were treated with YM254890 (100 nM) for 1h prior peptide treatments. EGFR internalization following hUII, hUT-Pep2, or [Trp¹, Leu²]hUT-Pep3 stimulation (10⁻⁶ M) was visualized by green fluorescence using a single sequential line of excitation on a Zeiss LSM 780 Axio Observer Z1 (Carl Zeiss Microimaging). EGFR-GFP internalization was visualized using a combination of excitation (488 nm) and emission filters (499 and 520 nm).

Proliferation assays

HEK 293-hUT cell proliferation was evaluated by flow cytometry using propidium iodide DNA staining. Cells, grown in 6-well plates to 80% confluency, were starved for 6 h in a serum-free medium and then treated with hUII, hUT-Pep2, or [Trp¹, Leu²]hUT-Pep3 (10⁻⁶ M) for 30 minutes at RT. Next, cells were detached, fixed with cold 70% ethanol and then stored at -20°C for at least 2 h. Cells were centrifuged at 200 rpm for 10 min at 4°C and washed at least once with cold PBS. Cells were then resuspended in Triton X-100 (0.1%) supplemented with propidium iodide (500 μ g/mL), and 200 μ g/mL of DNase-free RNase A in PBS. Data, expressed as the mean \pm SEM of at least three independent experiments, were acquired on a FACScan (BD Biosciences, San Jose, CA, USA) and results were analyzed with the FlowJo v10 software. The proliferation index is defined as the

total number of divisions divided by the number of cells that went into division.

Rat aortic ring contraction

Adult male Sprague-Dawley rats (Charles-River, Saint-Constant, Qc, Canada) weighing 250–300 g were housed in cages under controlled illumination (12:12 h light-dark cycle), humidity, and temperature (21–23°C) and had free access to tap water and rat chow. All experimental procedures were performed in accordance with regulations and ethical guidelines from the Canadian Council for the Care of Laboratory Animals and received approvals of the institutional animal care and use committee of the *Institut National de la Recherche Scientifique - Centre Armand-Frappier Santé Biotechnologie*. As previously described,^(17,18) the thoracic aorta was cleared of surrounding tissue and then excised from the aortic arch to the diaphragm. Conjunctive tissues were next removed from the thoracic aorta and the vessels were divided into 5 rings of 4 mm. The endothelium of each aortic ring was removed by gently rubbing the vessel intimal surface. Aortic rings were then placed in a 5 mL organ bath filled with oxygenated normal Krebs-Henselheit buffer. Eighty microliters of a 2.5 M potassium chloride solution (40 mM final concentration) were used to evaluate maximal contractile responses of each vessel. In one bath, hUII (10^{-6} M) was applied as a control, and the tissue-response was expressed as the ratio with the KCl-induced contraction. Cumulative concentration-response curves to synthetic peptides were obtained by increasing the concentration of each peptide in the remaining organ chambers (10^{-11} to 10^{-5} M). The amplitude of the contraction induced by each concentration of peptide was expressed as a percentage of the KCl-induced contraction divided by the tissue-response induced by hUII. Antagonist activity of hUT-derived peptiducins was evaluated by exposing first the aortic ring to hUT-Pep2, or [Trp¹, Leu²]hUT-Pep3 (10^{-5} M) for 30 min, to ensure that the peptide reached equilibrium and that no agonist effect is observed, and then adding cumulative concentration of hUII or URP (10^{-12} – 10^{-6} M). The median effective concentrations (EC₅₀) are expressed as the mean ± S.E.M., and the *n* values, representing the total number of animals from which the vessels were isolated, varied from 5–8 animals.

Rat neonatal fibroblast proliferation

Neonatal rat fibroblasts, endogenously expressing UT (75), were obtained from 1–3 days old Sprague-Dawley pups as previously reported (76). Briefly, hearts obtained from neonatal rats were enzyme-digested and after centrifugation, cells were pre-plated to separate cardiomyocytes from fibroblasts. As reported, the adherent nonmyocyte fractions correspond predominantly to fibroblasts while the supernatants largely contain the cardiomyocytes. After several washes, attached fibroblasts were trypsinized and then cultured at 37°C in 96-well plate (6,000 cells per well) in low glucose-DMEM supplemented with 7% FBS, 100 units/mL of penicillin, and 100 µg/mL of streptomycin. After 48 h, cells were washed twice with low glucose-DMEM, and starved for 12 h in this medium. Cells were then treated for 24 h with hUII, hUT-Pep2, or [Trp¹, Leu²]hUT-Pep3 at a concentration of 10^{-6} M. Prior to staining, cells were fixed with 4% paraformaldehyde for 15 min at RT, permeabilized with 0.2% Triton X-100 in PBS for 5 min, and then blocked with 10% horse serum in PBS for 1 h at RT. Cells are incubated with primary anti-smooth muscle α -actin antibody (1/500) in 10% horse serum/PBS overnight at 4°C and later with secondary anti-rabbit Alexa Fluor 488 (1/1000) for 1 h at RT. Cell staining was performed using cell mask (1 µg/mL) in PBS for 30 min at room temperature and with Hoechst dye in PBS (1 µg/mL) for 10 min. Analysis was performed on an Opera Phoenix High Content Imaging System with a 20x water objective.

Data availability

The ensemble of hUT-Pep2 NMR-derived structures has been deposited in the Protein Data Bank (PDB) with the following code: 6HVK. All remaining data are contained within the article.

Statistical analysis

All experiments were performed at least in triplicate. Data, expressed as mean ± S.E.M., were analyzed with the Prism Software (Graphpad Software, San Diego, CA, USA). Sigmoidal concentration-response curves fitted with variable slope were used to determine EC₅₀. Statistical

comparisons were analyzed by the Student's t-test, and differences were considered significant where $*P < 0.05$, $**P < 0.01$ or $***P < 0.001$.

Acknowledgements: This work was supported by a grant from the Heart and Stroke Foundation of Canada (G-15-0008938) and the Canadian Institutes of Health Research (PJT-159687) to T.E.H. and J.C.T, a grant from the Canadian Institutes of Health Research to D.C. (MOP-142184) and a grant from the Natural Sciences and Engineering Research Council of Canada (RGPIN-2015-04848) to D.C. R.D.M. was supported by studentships from the McGill-CIHR Drug Development Training Program and the McGill Faculty of Medicine and Health Sciences. H.N. was supported by a fellowship from the *Fonds de Recherche en Santé du Québec*. J.C.C.D was supported by the Barbara & Edward Victor award granted by McGill Faculty of Medicine.

Conflict of interest: The authors declare that they have no conflicts of interest.

References

1. Vaudry, H., Leprince, J., Chatenet, D., Fournier, A., Lambert, D. G., Le Mevel, J. C., Ohlstein, E. H., Schwertani, A., Tostivint, H., and Vaudry, D. (2015) International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. *Pharmacological reviews* **67**, 214-258
2. Nassour, H., Iddir, M., and Chatenet, D. (2019) Towards Targeting the Urotensinergic System: Overview and Challenges. *Trends Pharmacol Sci* **40**, 725-734
3. Watson, A. M., Olukman, M., Koulis, C., Tu, Y., Samijono, D., Yuen, D., Lee, C., Behm, D. J., Cooper, M. E., Jandeleit-Dahm, K. A., Calkin, A. C., and Allen, T. J. (2013) Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. *Diabetologia* **56**, 1155-1165
4. You, Z., Genest, J., Jr., Barrette, P. O., Hafiane, A., Behm, D. J., D'Orleans-Juste, P., and Schwertani, A. G. (2012) Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequelae in mice. *Arteriosclerosis, thrombosis, and vascular biology* **32**, 1809-1816
5. Zhao, J., Xie, L. D., Song, C. J., Mao, X. X., Yu, H. R., Yu, Q. X., Ren, L. Q., Shi, Y., Xie, Y. Q., Li, Y., Liu, S. S., and Yang, X. H. (2014) Urotensin II improves atherosclerosis by controlling C-reactive protein, monocyte chemoattractant protein-1 and transforming growth factor-beta expression in rats. *Exp Ther Med* **7**, 1647-1652
6. Zhao, J., Yu, Q. X., Kong, W., Gao, H. C., Sun, B., Xie, Y. Q., and Ren, L. Q. (2013) The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats. *Exp Ther Med* **5**, 1765-1769
7. Lee, J. H., Park, B. K., Oh, K. S., Yi, K. Y., Lim, C. J., Seo, H. W., and Lee, B. H. (2016) A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. *International immunopharmacology* **40**, 196-202
8. Pehlivan, Y., Dokuyucu, R., Demir, T., Kaplan, D. S., Koc, I., Orkmez, M., Turkbeyler, I. H., Ceribasi, A. O., Tutar, E., Taysi, S., Kisacik, B., and Onat, A. M. (2014) Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension. *Inflammation* **37**, 1280-1288
9. Wang, Y., Tian, W., Xiu, C., Yan, M., Wang, S., and Mei, Y. (2019) Urotensin II improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model. *Clinical rheumatology* **38**, 29-35
10. Bousette, N., Hu, F., Ohlstein, E. H., Dhanak, D., Douglas, S. A., and Giaid, A. (2006) Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. *J Mol Cell Cardiol* **41**, 285-295
11. Bousette, N., Pottinger, J., Ramli, W., Ohlstein, E. H., Dhanak, D., Douglas, S. A., and Giaid, A. (2006) Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. *Peptides* **27**, 2919-2926

12. Oh, K. S., Lee, J. H., Yi, K. Y., Lim, C. J., Park, B. K., Seo, H. W., and Lee, B. H. (2017) A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure. *European journal of pharmacology* **799**, 94-102
13. Billard, E., Iddir, M., Nassour, H., Lee-Gosselin, L., Poujol de Molliens, M., and Chatenet, D. (2018) New directions for urotensin II receptor ligands. *Peptide Science*, e24056
14. Kim, S. K., Li, Y., Park, C., Abrol, R., and Goddard, W. A., 3rd. (2010) Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations. *ChemMedChem* **5**, 1594-1608
15. Brancaccio, D., Merlino, F., Limatola, A., Yousif, A. M., Gomez-Monterrey, I., Campiglia, P., Novellino, E., Grieco, P., and Carotenuto, A. (2015) An investigation into the origin of the biased agonism associated with the urotensin II receptor activation. *J Pept Sci* **21**, 392-399
16. Merlino, F., Billard, E., Yousif, A. M., Di Maro, S., Brancaccio, D., Abate, L., Carotenuto, A., Bellavita, R., d'Emmanuele di Villa Bianca, R., Santicioli, P., Marinelli, L., Novellino, E., Hebert, T. E., Lubell, W. D., Chatenet, D., and Grieco, P. (2019) Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides. *J Med Chem* **62**, 1455-1467
17. Chatenet, D., Letourneau, M., Nguyen, Q. T., Doan, N. D., Dupuis, J., and Fournier, A. (2013) Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation. *Br J Pharmacol* **168**, 807-821
18. Chatenet, D., Nguyen, Q. T., Letourneau, M., Dupuis, J., and Fournier, A. (2012) Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. *Biochem Pharmacol* **83**, 608-615
19. Doan, N. D., Nguyen, T. T., Letourneau, M., Turcotte, K., Fournier, A., and Chatenet, D. (2012) Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart. *Br J Pharmacol* **166**, 243-257
20. Jarry, M., Diallo, M., Lecointre, C., Desrues, L., Tokay, T., Chatenet, D., Leprince, J., Rossi, O., Vaudry, H., Tonon, M. C., Prezeau, L., Castel, H., and Gandolfo, P. (2010) The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. *Biochem J* **428**, 113-124
21. Prosser, H. C., Forster, M. E., Richards, A. M., and Pemberton, C. J. (2008) Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. *Peptides* **29**, 770-777
22. Billard, E., Hebert, T. E., and Chatenet, D. (2018) Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue. *J Med Chem* **61**, 8707-8716
23. Billard, E., Letourneau, M., Hebert, T. E., and Chatenet, D. (2017) Insight into the role of urotensin II-related peptide tyrosine residue in UT activation. *Biochem Pharmacol*, 100-107
24. Douchez, A., Billard, E., Hebert, T. E., Chatenet, D., and Lubell, W. D. (2017) Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics. *J Med Chem* **60**, 9838-9859
25. Dufour-Gallant, J., Chatenet, D., and Lubell, W. D. (2015) De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one gamma-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo. *J Med Chem* **58**, 4624-4637
26. Merlino, F., Yousif, A. M., Billard, E., Dufour-Gallant, J., Turcotte, S., Grieco, P., Chatenet, D., and Lubell, W. D. (2016) Urotensin II((4-11)) Azasulfuryl Peptides: Synthesis and Biological Activity. *J Med Chem* **59**, 4740-4752
27. Strack, M., Billard, E., Chatenet, D., and Lubell, W. D. (2017) Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II. *Bioorg Med Chem Lett* **27**, 3412-3416
28. Kenakin, T. (2012) The potential for selective pharmacological therapies through biased receptor signaling. *BMC Pharmacol Toxicol* **13**, 3

29. Kenakin, T. (2011) Functional selectivity and biased receptor signaling. *J Pharmacol Exp Ther* **336**, 296-302
30. Chaturvedi, M., Schilling, J., Beaudrait, A., Bouvier, M., Benovic, J. L., and Shukla, A. K. (2018) Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. *Trends Biochem Sci* **43**, 533-546
31. Dimond, P., Carlson, K., Bouvier, M., Gerard, C., Xu, L., Covic, L., Agarwal, A., Ernst, O. P., Janz, J. M., Schwartz, T. W., Gardella, T. J., Milligan, G., Kuliopulos, A., Sakmar, T. P., and Hunt, S. W., 3rd. (2011) G protein-coupled receptor modulation with pepducins: moving closer to the clinic. *Ann N Y Acad Sci* **1226**, 34-49
32. Carlson, K., McMurry, T., and Hunt, S. W., 3rd. (2012) Pepducins: lipopeptide allosteric modulators of GPCR signaling. *Drug discovery today. Technologies* **9**, e1-e70
33. Covic, L., Gresser, A. L., Talavera, J., Swift, S., and Kuliopulos, A. (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. *Proceedings of the National Academy of Sciences of the United States of America* **99**, 643-648
34. Covic, L., Misra, M., Badar, J., Singh, C., and Kuliopulos, A. (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. *Nat Med* **8**, 1161-1165
35. Kaneider, N. C., Agarwal, A., Leger, A. J., and Kuliopulos, A. (2005) Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. *Nat Med* **11**, 661-665
36. Quoyer, J., Janz, J. M., Luo, J., Ren, Y., Armando, S., Lukashova, V., Benovic, J. L., Carlson, K. E., Hunt, S. W., 3rd, and Bouvier, M. (2013) Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. *Proceedings of the National Academy of Sciences of the United States of America* **110**, E5088-5097
37. Carr, R., 3rd, Du, Y., Quoyer, J., Panettieri, R. A., Jr., Janz, J. M., Bouvier, M., Kobilka, B. K., and Benovic, J. L. (2014) Development and characterization of pepducins as Gs-biased allosteric agonists. *J Biol Chem* **289**, 35668-35684
38. Tressel, S. L., Koukos, G., Tchernychev, B., Jacques, S. L., Covic, L., and Kuliopulos, A. (2011) Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. *Methods Mol Biol* **683**, 259-275
39. O'Callaghan, K., Kuliopulos, A., and Covic, L. (2012) Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. *J Biol Chem* **287**, 12787-12796
40. Saviello, M. R., Malfi, S., Campiglia, P., Cavalli, A., Grieco, P., Novellino, E., and Carotenuto, A. (2010) New insight into the mechanism of action of the temporin antimicrobial peptides. *Biochemistry* **49**, 1477-1485
41. Doreleijers, J. F., Rullmann, J. A., and Kaptein, R. (1998) Quality assessment of NMR structures: a statistical survey. *J Mol Biol* **281**, 149-164
42. Zhang, P., Leger, A. J., Baleja, J. D., Rana, R., Corlin, T., Nguyen, N., Koukos, G., Bohm, A., Covic, L., and Kuliopulos, A. (2015) Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics. *J Biol Chem* **290**, 15785-15798
43. Brule, C., Perzo, N., Joubert, J. E., Sainsily, X., Leduc, R., Castel, H., and Prezeau, L. (2014) Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors. *FASEB J* **28**, 5148-5162
44. He, Y. H., Hong, J. M., Guo, H. S., Wei, J. R., Chen, H., Zuo, H. H., and Li, Z. L. (2004) [Effects of urotensin II on cultured cardiac fibroblast proliferation and collagen type I mRNA expression]. *Di Yi Jun Yi Da Xue Xue Bao* **24**, 505-508
45. Zhang, Y. G., Li, J., Li, Y. G., and Wei, R. H. (2008) Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. *J Hypertens* **26**, 1119-1126
46. Luttrell, L. M., Maudsley, S., and Bohn, L. M. (2015) Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. *Mol Pharmacol* **88**, 579-588

47. Gurbel, P. A., Bliden, K. P., Turner, S. E., Tantry, U. S., Gesheff, M. G., Barr, T. P., Covic, L., and Kuliopulos, A. (2016) Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. *Arteriosclerosis, thrombosis, and vascular biology* **36**, 189-197
48. Armstrong, C. W. D., Coulter, J. A., Ong, C. W., Maxwell, P. J., Walker, S., Butterworth, K. T., Lyubomska, O., Berlinger, S., Gallagher, R., O'Sullivan, J. M., Jain, S., Mills, I. G., Prise, K. M., Bristow, R. G., LaBonte, M. J., and Waugh, D. J. J. (2020) Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. *NAR cancer* **2**, zcaa012
49. Kuliopulos, A., Gurbel, P. A., Rade, J. J., Kimmelstiel, C. D., Turner, S. E., Bliden, K. P., Fletcher, E. K., Cox, D. H., and Covic, L. (2020) PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. *Arteriosclerosis, thrombosis, and vascular biology*, ATVBaha120315168
50. Carr, R., 3rd, and Benovic, J. L. (2016) From biased signalling to polypharmacology: unlocking unique intracellular signalling using pepducins. *Biochem Soc Trans* **44**, 555-561
51. Fan, G. H., Zhou, T. H., Zhang, W. B., and Pei, G. (1998) Suppression of phospholipase C blocks Gi-mediated inhibition of adenylyl cyclase activity. *European journal of pharmacology* **341**, 317-322
52. Wu, Y. L., Pei, G., and Fan, G. H. (1998) Inhibition of phospholipase C blocks opioid receptor-mediated activation of Gi proteins. *Neuroreport* **9**, 99-103
53. Belcheva, M. M., and Coscia, C. J. (2002) Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. *Neurosignals* **11**, 34-44
54. Blaukat, A., Barac, A., Cross, M. J., Offermanns, S., and Dikic, I. (2000) G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Gα_q and Gα_i signals. *Mol Cell Biol* **20**, 6837-6848
55. Esposito, G., Perrino, C., Cannavo, A., Schiattarella, G. G., Borgia, F., Sannino, A., Pironti, G., Gargiulo, G., Di Serafino, L., Franzone, A., Scudiero, L., Grieco, P., Indolfi, C., and Chiariello, M. (2011) EGFR trans-activation by urotensin II receptor is mediated by beta-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. *Basic research in cardiology* **106**, 577-589
56. Grundmann, M., Merten, N., Malfacini, D., Inoue, A., Preis, P., Simon, K., Ruttiger, N., Ziegler, N., Benkel, T., Schmitt, N. K., Ishida, S., Muller, I., Reher, R., Kawakami, K., Inoue, A., Rick, U., Kuhl, T., Imhof, D., Aoki, J., Konig, G. M., Hoffmann, C., Gomeza, J., Wess, J., and Kostenis, E. (2018) Lack of beta-arrestin signaling in the absence of active G proteins. *Nature communications* **9**, 341
57. Kobilka, B. K., and Deupi, X. (2007) Conformational complexity of G-protein-coupled receptors. *Trends in pharmacological sciences* **28**, 397-406
58. Devost, D., Sleno, R., Petrin, D., Zhang, A., Shinjo, Y., Okde, R., Aoki, J., Inoue, A., and Hebert, T. E. (2017) Conformational Profiling of the AT1 Angiotensin II Receptor Reflects Biased Agonism, G Protein Coupling, and Cellular Context. *J Biol Chem* **292**, 5443-5456
59. Granier, S., and Kobilka, B. (2012) A new era of GPCR structural and chemical biology. *Nat Chem Biol* **8**, 670-673
60. Sauzeau, V., Le Mellionnec, E., Bertoglio, J., Scalbert, E., Pacaud, P., and Loirand, G. (2001) Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. *Circ Res* **88**, 1102-1104
61. Tsuji, M., Ueda, S., Hirayama, T., Okuda, K., Sakaguchi, Y., Isono, A., and Nagasawa, H. (2013) FRET-based imaging of transbilayer movement of pepducin in living cells by novel intracellular bioreductively activatable fluorescent probes. *Org Biomol Chem* **11**, 3030-3037
62. Hwang, T. L., and Shaka, A. J. (1995) Water Suppression that Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients. *J. Magn. Reson.* **112**, 275-279

63. Marion, D., and Wuthrich, K. (1983) Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of ¹H-¹H spin-spin coupling constants in proteins. *Biochem Biophys Res Commun* **113**, 967-974
64. Piantini, U., Sorensen, O. W., and Ernst, R. R. (1982) Multiple Quantum Filters for Elucidating NMR Coupling Network. *J. Am. Chem. Soc.* **104**, 6800-6801
65. Braunschweiler, L., and Ernst, R. R. (1983) Coherence Transfer by Isotropic Mixing: Application to Proton Correlation Spectroscopy. *J. Magn. Res.* **53**, 521-528
66. Jenner, J., Meyer, B. H., Bachman, P., and Ernst, R. R. (1979) Investigation of Exchange Processes by Two-Dimensional NMR Spectroscopy. *J. Chem. Phys.* **71**, 4546-4553
67. States, D. J., Haberkorn, R. A., and Ruben, D. J. (1982) A Two-Dimensional Nuclear Overhauser Experiment with Pure Absorption Phase in Four Quadrants. *J. Magn. Reson.* **42**, 286-292
68. Bartels, C., Xia, T., Billeter, M., Guentert, P., and Wüthrich, K. (1995) The Program XEASY for Computer-Supported NMR Spectral Analysis of Biological Macromolecules. *J. Biomol. NMR* **6**, 1-10
69. Wüthrich, K. (1986) In NMR of Proteins and Nucleic Acids. *John Wiley & Sons: New York*
70. Güntert, P., Mumenthaler, C., and Wüthrich, K. (1997) Torsion angle dynamics for NMR structure calculation with the new program DYANA. *J Mol Biol* **273**, 283-298
71. Maple, J. R., Dinur, U., and Hagler, A. T. (1988) Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. *Proceedings of the National Academy of Sciences of the United States of America* **85**, 5350-5354
72. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605-1612
73. Breton, B., Sauvageau, E., Zhou, J., Bonin, H., Le Gouill, C., and Bouvier, M. (2010) Multiplexing of multicolor bioluminescence resonance energy transfer. *Biophys J* **99**, 4037-4046
74. Lukasheva, V., Devost, D., Le Gouill, C., Namkung, Y., Martin, R. D., Longpre, J. M., Amraei, M., Shinjo, Y., Hogue, M., Lagace, M., Breton, B., Aoki, J., Tanny, J. C., Laporte, S. A., Pineyro, G., Inoue, A., Bouvier, M., and Hebert, T. E. (2020) Signal profiling of the beta1AR reveals coupling to novel signalling pathways and distinct phenotypic responses mediated by beta1AR and beta2AR. *Scientific reports* **10**, 8779
75. Zhang, Y. G., Li, Y. G., Liu, B. G., Wei, R. H., Wang, D. M., Tan, X. R., Bu, D. F., Pang, Y. Z., and Tang, C. S. (2007) Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. *Acta Pharmacol Sin* **28**, 36-43
76. Colombo, F., Gosselin, H., El-Helou, V., and Calderone, A. (2003) Beta-adrenergic receptor-mediated DNA synthesis in neonatal rat cardiac fibroblasts proceeds via a phosphatidylinositol 3-kinase dependent pathway refractory to the antiproliferative action of cyclic AMP. *J Cell Physiol* **195**, 322-330

FOOTNOTES

We thank the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC) and Heart and Stroke Canada for funding.

Abbreviations. 7TMR, 7-transmembrane receptor; BRET, bioluminescence resonance energy transfer; BOP, (benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate; CHO cells, Chinese hamster ovary cells; DCM, dichloromethane; DIEA, N,N-diisopropylethylamine; DMF, dimethylformamide; DPC, dodecylphosphocholine; DQF-COSY, double quantum filtered correlated spectroscopy; Fmoc, fluorenylmethyloxycarbamate; GPCR, G protein-coupled receptor; HEK 293 cells, human embryonic kidney 293 cells; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight; NMR, nuclear magnetic resonance; NOESY, nuclear Overhauser enhancement spectroscopy; RP-HPLC, reverse phase-high performance liquid chromatography; TOCSY, total correlated spectroscopy;

TSP, 3-(trimethylsilyl)propionic acid; UII, urotensin II; URP, urotensin II-related peptide; UT, urotensin II receptor.

Table 1. Amino acid sequences and analytical data of compounds hUII, URP, and hUT-derived pepducins.

Cpd Name	Sequence	MW ^a calc	MS ^b found
hUII	H-Glu-Thr-Pro-Asp-[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH	1387.6	1388.1
URP	H-Ala-[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH	1016.4	1016.4
hUT-Pep2	Palm-Arg-Pro-Leu-Asp-Thr-Val-Gln-Arg-Pro-Lys-Gly-Tyr-NH ₂	1666.0	1667.1
[Trp ¹ , Leu ²]hUT-Pep3	Palm-Trp-Leu-Ser-Gln-Arg-Ala-Ser-Phe-Lys-Arg-Ala-Arg-Arg-NH ₂	1899.3	1899.9

^a Molecular weight calculated on a CEM Liberty Blue peptide synthesizer software. ^b MALDI-TOF mass spectral analysis (m/z). Values represent the observed m/z of the monoisotope [M + H]⁺ ions. Palm: palmitoyl.

Table 2. Signaling signatures of hUII and hUT-derived pepducins

Peptides	G _q		G ₁₂		G _i		β-arr1		β-arr2	
	pEC ₅₀ ^a	E _{max} ^b	pEC ₅₀ ^a	E _{max} ^b	pEC ₅₀ ^a	E _{max} ^b	pEC ₅₀ ^a	E _{max} ^b	pEC ₅₀ ^a	E _{max} ^b
hUII	8.19 ± 0.12	109 ± 5	8.62 ± 0.09	98 ± 3	10.18 ± 0.07	93 ± 2	8.66 ± 0.13	104 ± 4	9.33 ± 0.14	100 ± 3
hUT-Pep2	7.31 ± 0.55**	9 ± 1***	-	-	10.09 ± 0.08	96 ± 2	-	-	-	15 ^c
[Trp ¹ , Leu ²]hUT-Pep3	8.34 ± 0.33	29 ± 4***	-	5 ^c	10.39 ± 0.09	97 ± 2	8.08 ± 0.27**	18 ± 2***	7.74 ± 0.32***	19 ± 3***

^apEC₅₀ = -log EC₅₀. ^bThe maximum efficacy is expressed as a percentage of the activation induced by hUII (10⁻⁶M). ^cMaximum efficacy at 10⁻⁶M. All values are expressed as mean ± SEM. Statistical analysis were performed using unpaired Student's t test, ***P* ≤ 0.01, ****P* ≤ 0.001, versus values obtained for hUII. Each replicate (n = 3-5) was conducted on different cellular passages.

Table 2. Contractile activity of UT-derived pepducins.

	E_{\max}^a	pEC_{50}^b	n
hUII	102 ± 3	8.64 ± 0.09	22
URP	108 ± 3	8.10 ± 0.06	22
hUT-Pep2	7% @ 10 μ M	<5	5
[Trp ¹ , Leu ²]hUT-Pep3	16% @ 10 μ M	<5	5

^aMaximum efficacy is expressed as a percentage of the amplitude of the contraction induced by KCl (40 mM). All values are expressed as mean \pm SEM. Each replicate (n) was conducted on tissue from different animals.

Table 4. Antagonist contractile activities.

<i>Peptide</i>	Aortic ring contraction hUII			Aortic ring contraction URP		
	n	pEC ₅₀	E _{max} ^a	n	pEC ₅₀	E _{max} ^a
hUII	19	8.69 ± 0.08	100 ± 3			
URP				22	8.09 ± 0.06	105 ± 3
hUT-Pep2	5	8.00 ± 0.11**	86 ± 3*	5	7.60 ± 0.31	76 ± 8**
[Trp ¹ , Leu ²]hUT-Pep3	5	8.57 ± 0.63	35 ± 6***	5	8.59 ± 0.12	16 ± 2***

Aortic rings were pre-treated with different analogues at a concentration of 10⁻⁶M for 30 minutes prior to hUII or URP treatment. ^aMaximum efficacy is expressed as a percentage of the KCl-induced contraction (40 mM) divided by the tissue-response induced by hUII or URP (10⁻⁶M). All values are expressed as mean ± SEM. Statistical analysis were performed using unpaired Student's t test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, versus values obtained for hUII or URP. Each replicate (n) was conducted on tissue from different animals.



A**B**

Figure 1. Cytotoxic action of UT-pepducins. Toxicity of UT-Pep2 and UT-Pep3 were evaluated using (A) MTT or (B) LDH assays in HEK 293-hUT cells




Figure 2. 3D structural data of UT-derived pepducins. (A) Modeled structure of the hUT-Pep2. Ensemble of the 10 lowest energy conformers of hUT-Pep2. Structures were superimposed using the backbone heavy atoms. Side chain heavy atoms are shown with different colours (carbon, green; nitrogen, blue; oxygen, red). Many hydrogen atoms and the lipid chains are not shown for clarity. Backbone structure is represented as green ribbon. (B) Superposition of hUT-Pep2 structure (representing the NMR lowest energy conformer, green) and the second intracellular loop of a hUT model (orange). (C) Circular dichroism of [Trp¹, Leu²]hUT-Pep3 in various solvents.




Figure 3. IP₁ (A and B) and ERK_{1/2} phosphorylation (C and D) kinetics and concentration-dependent stimulation following hUT receptor activation. IP₁ production was evaluated using the IP-One terbium immunoassay kits while ERK_{1/2} phosphorylation was measured by western blot in CHO-K1 cells stably expressing the hUT receptor. The data are normalized to the hUII maximum effect. Each curve represents the mean \pm SEM of at least three independent experiments performed in triplicate.




Figure 4. ERK_{1/2} phosphorylation profile after hUT receptor activation. ERK_{1/2} phosphorylation was measured by western blot in CHO-K1 cells or CHO-K1 cells stably expressing the hUT receptor. (A) ERK_{1/2} phosphorylation normalized to total ERK was measured following hUII (10⁻⁷M), hUT-Pep2, or [Trp¹, Leu²]hUT-Pep3 (10⁻⁶M) treatments in CHO-K1 or CHO-K1-hUT cells. (B-D) The hUT receptor was activated by hUT-Pep2, or [Trp¹, Leu²]hUT-Pep3 (10⁻⁶M) under control conditions, or after treatment with PTX, U73122 or AG1478. The data are normalized to the UII maximum effect in B, C and D. Each curve represents the mean \pm SEM of at least three independent experiments performed in triplicate.




Figure 5. ERK_{1/2} phosphorylation kinetics after hUT receptor activation. Activation of hUT by hUII, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 under control conditions or after treatment with YM254890. Data are normalized to the hUII maximum effect. Curves represent means \pm sem of 3 independent kinetic experiments performed in triplicate.




Figure 6. Signaling signature of UT-pepducins following UT receptor activation. BRET measurements were performed following hUT stimulation with increasing concentrations of hUII, or UT-derived pepducins in HEK 293-hUT cells. The data are normalized to maximal hUII responses (10⁻⁶M). Each curve represents the mean ± SEM of at least three independent concentration-response experiments performed in triplicate.




Figure 7. UT-pepdudin-mediated transactivation of EGFR following hUT activation. HEK 293 cells stably expressing wild type hUT (B, E, H, K) or not (A, D, G, J) and transfected with FLAG-EGFR were treated with hUII, hUT-Pep2, or [Trp¹, Leu²]hUT-Pep3 in the presence (C, F, I, L) or not of YM254890. EGFR internalization, following hUT stimulation with various ligands for 30 min, was visualized using confocal microscopy. The images shown are from representative experiment repeated at least three times.




Figure 8. Effects of hUII and UT-derived pepducins on proliferation of hUT receptor-expressing HEK 293 cell and rat neonatal fibroblasts. HEK 293 cells stably expressing hUT were treated with hUII, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 (10^{-6} M) and cell proliferation was evaluated by MTT assay (A) or flow cytometry (C). HEK 293 cells were treated with hUII, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 (10^{-6} M) and cell proliferation was also evaluated by MTT assay (B). (D) Rat neonatal fibroblasts endogenously expressing UT were treated with hUII, hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3 (10^{-6} M) and proliferation was evaluated with an Opera Phenix using smooth muscle α -actin as primary antibody and an anti-rabbit Alexa Fluor 488 as secondary antibody. Each bar corresponds to the mean \pm SEM obtained from 3 independent experiments conducted in triplicate.




Figure 9. Vasocontractile action of UT-derived pepducins. (A) Representative concentration-response curves obtained with rat thoracic aortic rings after adding cumulative concentrations of hUII or UT-derived pepducins. Representative concentration-response curves obtained with rat thoracic aortic rings after adding cumulative concentrations of hUII (B) or URP (C) following pre-treatment with hUT-Pep2 or [Trp¹, Leu²]hUT-Pep3. Each replicate (n) was conducted on tissue from at least 3 different animals. Data represent mean \pm S.E.M.